CTLA4 and melanoma: While multiple studies in melanoma brain metastases report intracranial objective responses with anti-PD-1 and/or anti-CTLA-4 immunotherapy, the evidence in NSCLSC BMs is limited to anti-PD-1 immunotherapy (i.e., predominantly nivolumab).